Navigation Links
Arcion Therapeutics' Topical Gel Candidate, ARC-4558, Demonstrates Significant Pain Reduction in Phase 2b Trial for Painful Diabetic Neuropathy (PDN)
Date:7/20/2010

BALTIMORE, July 20 /PRNewswire/ -- Arcion Therapeutics, a venture backed clinical stage biotechnology company developing topical therapies for chronic pain, today announced top-line results from a successful Phase 2b double-blind, randomized, placebo-controlled clinical trial of its lead topical pain candidate, ARC-4558, in adult patients with painful diabetic neuropathy (PDN).  Arcion recently held an End of Phase 2 meeting with the United States Food and Drug Administration (FDA) and the ARC-4558 program is now poised to enter Phase 3 studies. ARC-4558 is a 0.1% gel formulation of clonidine hydrochloride for topical administration.

The study results successfully demonstrated therapeutic potential for treating PDN with ARC-4558 by targeting abnormal nerve signaling at the level of the skin with a 0.1% topical gel formulation of clonidine.  ARC-4558 was most effective in reducing pain in subjects with evidence of preserved nociceptors (nerve fibers responsible for pain signaling) in the skin.  In subjects with at least minimal nociceptor function, ARC-4558 was significantly more effective in reducing pain than placebo (p<0.05). The significance of the response increased with higher levels of nociceptors in the subject's skin (p<0.005).  ARC-4558 did not demonstrate efficacy in subjects lacking evidence of preserved nociceptor function.  

The ITT (intent to treat) population was comprised of a mix of subjects in which about half had little or no nociceptor preservation and therefore the pooled results were not significant.  Plasma levels of clonidine were consistently
'/>"/>

SOURCE Arcion Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anesiva Announces Merger With Arcion Therapeutics Will Not be Completed
2. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
3. Elusys Therapeutics and Lonza Extend Manufacturing Agreement for Anthim, a New Anthrax Treatment in Late-Stage Development
4. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
5. Nile Therapeutics Completes Dosing of Phase II Study
6. Cornerstone Therapeutics Announces Management Change
7. Nonconformity of NOV002 Used in Phase 3 NSCLC Trial Sponsored by Novelos Therapeutics, Inc to NOV002 (Glutoxim(R)), Used in Phase 1/2 NSCLC and all Previous Trials
8. InteKrin Therapeutics Presented Phase 2b Clinical Data at the 2010 American Diabetes Association Annual Meeting, Demonstrating Improved Glycemic Control in Patients with Type 2 Diabetes Without Causing the Edema Seen with Pioglitazone
9. Global Melanoma Therapeutics Industry
10. Tolera Therapeutics Granted Orphan Drug Designation for Treatment of Type 1 diabetes mellitus
11. TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014  Decision Resources Group finds that ... (ID) specialists are willing to prescribe Durata,s Dalvance ... use as OPAT, approximately two-thirds of the respondents ... their hospital inpatients. However, our findings indicate that ... initiated on OPAT following hospital discharge, and most ...
(Date:7/10/2014)... July 10, 2014 CVS Caremark Corporation (NYSE: ... has approved a quarterly dividend of $0.275 (27.5 cents) per ... on August 1, 2014, to holders of record on July ... CVS Caremark is dedicated to helping people on their path ... the United States . Through the company,s ...
(Date:1/15/2014)... Jan. 15, 2014 Sono-Tek Corporation (OTC BB: SOTK) today ... 30, 2013, compared to sales of $2,202,000 for the prior ... this quarter has also shown growth over the preceding quarter,s ... of this fiscal year. Markets that experienced sales increases over ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4
... Mass., Jan. 4, 2012  Halo Therapeutics, LLC, a ... fibrotic diseases, today announced that the United States ... designation for HT-100 for treatment of Duchenne muscular ... neuromuscular disorder, which afflicts approximately 1 in 3,500 ...
... Pa., Jan. 4, 2012  Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) ... 30th Annual J.P. Morgan Healthcare Conference to be held ... in San Francisco, CA.  Mr. Adrian Adams, Chief Executive ... of the Company and its product pipeline at 2:00 ...
Cached Medicine Technology:Halo Therapeutics' HT-100 Receives FDA's Orphan Designation for Duchenne Muscular Dystrophy 2Halo Therapeutics' HT-100 Receives FDA's Orphan Designation for Duchenne Muscular Dystrophy 3Auxilium Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference 2Auxilium Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference 3Auxilium Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference 4
(Date:7/11/2014)... MagicQuinceaneraDresses.com, the popular online supplier of special occasion gowns, ... dresses . The company’s new items are specially designed ... a large amount of money. They are all available ... company’s online shop has become a one stop platform ... addition to exquisite Quinceanera dresses, it also offers great ...
(Date:7/11/2014)... July 12, 2014 According to ... total market is expected to register a CAGR ... , Browse 71 market data tables and 76 ... on "C4ISR Market"., http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , Early ... http://www.marketsandmarkets.com/requestCustomization.asp?id=1315 , The report provides market ...
(Date:7/11/2014)... (PRWEB) July 11, 2014 Butler Mobility has ... Inclined Platform Lifts . Previously the two standard ... five new beautiful earth tone colors as standard colors at ... well in the home but will enhance the beauty of ... for any home color scheme or individual décor. , The ...
(Date:7/11/2014)... Dennis Thompson HealthDay Reporter ... born with HIV who was thought to be cured by ... showing detectable levels of the AIDS-causing virus in her bloodstream, ... nearly 4 years old, had remained virus-free even though she ... Doctors had hoped her remission would open the door to ...
(Date:7/11/2014)... As part of its morcellator ... has been closely monitoring the ongoing meeting of ... Obstetrics and Gynecology Devices Panel, which has been ... risks associated with the use of power morcellators ... report published by Dow Jones Business News, a ...
Breaking Medicine News(10 mins):Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Butler Mobility Products Announces Five New Standard Colors for Their Inclined Platform Lifts 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 2Health News:Mississippi Girl Thought Cured of HIV Shows Signs of Infection 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Financial Ties Between FDA Advisory Panel Members and Manufacturers of Power Morcellators 4
... evading the drugs used by oncologists to try and eliminate it. ... , Now, researchers at UCLA,s Jonsson Comprehensive ... around an inhibitor, Zelboraf, which targets the mutated BRAF gene. ... encodes proteins, called the exome, Jonsson Cancer Center scientists discovered that ...
... Cancer Center and colleagues from 11 other institutions in the ... association studies (GWAS) one from the U.S. and one ... genes found to be associated with epithelial ovarian cancer patient ... for treating epithelial ovarian cancer (EOC), the most lethal kind ...
... from Carnegie Mellon University,s Marcel Just provides an explanation ... communication disorders to restricted interests and gives scientists ... Autism has long been a scientific enigma, mainly due ... Published in the journal Neuroscience and Biobehavioral ...
... 2012 Married adults who undergo heart surgery are more ... the same surgery to survive the next three months, a ... survival rates for single people, during the most critical post-operative ... and lead author of the study, which appears in the ...
... the metabolic syndromedefined as having multiple risk factors associated ... of chronic kidney disease, according to a recent study ... of Clinical Endocrinology & Metabolism (JCEM). An ... have three or more of the following risk factors ...
... People with schizophrenia report improved functioning after ... to results announced today from a six-month pilot. ... People with Schizophrenia , was spearheaded by the ... and administered at 10 community behavioral health organizations ...
Cached Medicine News:Health News:UCLA scientists uncover mechanism for melanoma drug resistance 2Health News:UCLA scientists uncover mechanism for melanoma drug resistance 3Health News:Researchers find possible genetic keys to surviving epithelial ovarian cancer 2Health News:New brain imaging and computer modeling predicts autistic brain activity and behavior 2Health News:New brain imaging and computer modeling predicts autistic brain activity and behavior 3Health News:Marriage: A powerful heart drug in short supply 2Health News:High blood glucose levels may increase kidney disease in elderly populations 2Health News:Pilot program demonstrates measureable benefits for people with schizophrenia 2
... includes three major components: Blood pump, Cannulae, ... Driver. This system provides partial or total ... conventional therapy, is unable to maintain adequate ... support, blood flows from the natural heart ...
Datascope presents a unique new product for post-hemostasis puncture site management. Safeguard is the first product ever to combine a built-in inflatable bulb and a sterile dressing- providing adjus...
... catheter is inserted into the subclavian or ... vena cava. The Cool Line incorporates ... temperature-controlled saline flowing within a closed-loop design, ... circulation. The Cool Line combines two ...
... The Fortius catheter provides maximum ... to target temperature. The Fortius catheter ... design to provide the ultimate solution ... catheter is inserted percutaneously into the ...
Medicine Products: